Australian Pharma Stock News

Canaccord Genuity has initiated coverage on Elsight (ASX:ELS), highlighting the company’s role in connectivity solutions for drones and autonomous systems as defence spending by NATO countries responds to ongoing geopolitical tensions in Europe. See our latest analysis for Elsight. At the latest share price of A$7.88, Elsight has seen a 1-day share price return of 1.29% and a 30-day share price return of 38.98%. The 1-year total shareholder return is very large, signalling strong momentum...

Artificial intelligence sits at the center of many of today’s market conversations, from chip supply to cloud spending and software tools like ChatGPT, even as inflation, energy prices and interest rate expectations keep moving the macro backdrop. For investors who want focused exposure without having to sift through every AI headline, this AI Stocks screener targets companies directly tied to semiconductors, software, LLMs, ChatGPT, cloud and broader transformation. In this article, you will...

Generation Development Group (ASX:GDG) is back on radar after record FY2025 results and strong funds under management growth coincided with supportive Division 296 tax settings, which helped drive elevated trading and renewed investor interest. See our latest analysis for Generation Development Group. At A$3.73, Generation Development Group’s share price has seen a sharp 1-day share price return of 4.78% after record FY2025 results and strong funds under management growth, but remains under...

Helia Group Limited has appointed insurance veteran Mark Senkevics as its next CEO and Managing Director, effective on or before 1 December 2026, while confirming Craig Ward will move from Interim CFO to permanent CFO from 1 July 2026 as part of a planned leadership transition. These leadership changes come as analysts rework valuation models and reassess Helia’s position in Australia’s mortgage insurance market, highlighting how management execution could matter more as the industry adjusts...

Penny stocks often attract attention for their low share prices, but the real opportunity can lie in finding companies with healthier balance sheets and cleaner cash flows than the typical early stage stock. With inflation, interest rates and energy costs all pulling markets in different directions, many investors are looking for ways to target potential growth while trying to keep a closer eye on risk. This is where the Financially Fit Penny Stocks screener comes in. It focuses on lower...

With inflation signals, central bank decisions and export data all moving in different directions across major economies, many investors are looking for companies where internal conviction is just as important as external forecasts. Fast growing stocks with high insider ownership can offer that combination, where management and major shareholders are materially aligned with future outcomes. Our Fast Growing Stocks With High Insider Ownership screener focuses on companies that analysts and...

In recent days, Telix Pharmaceuticals and United Imaging Healthcare signed a memorandum of understanding for a research collaboration in the US to combine United Imaging’s advanced scanner, software and AI platforms with Telix’s molecular imaging products, initially centred on TLX101-Px for characterizing recurrent or progressive glioma under FDA review. This alliance underscores Telix’s push to integrate its radiopharmaceutical pipeline with cutting-edge imaging hardware and clinical...

Inflation data, fuel prices and interest rate expectations are moving together in ways that can quickly reshape which Australian stocks look appealing and which might struggle. The extension of the federal fuel excise cut and a modest pullback in headline inflation could ease cost pressures for some companies, while others tied to fuel supply or sensitive to underlying inflation may face tougher conditions. This article breaks down three stocks from the Australian Inflation and Fuel Price...

MFF Capital Investments (ASX:MFF) is back in focus after flagging a planned 23% lift in its FY26 dividend. This continues a pattern of annual dividend increases since 2018 that keeps income-focused investors watching closely. See our latest analysis for MFF Capital Investments. MFF Capital Investments’ recent dividend update comes after a period of strong price momentum, with a 90 day share price return of 15.91% and a 1 year total shareholder return of 23.99% supporting a much stronger 3...

With inflation signals still flashing across regions, central banks keeping a tightening bias and energy markets feeding into bond yields, many investors are looking for clear, cash backed value rather than chasing momentum. The Undervalued Stocks Based On Cash Flows screener focuses on companies where discounted cash flow estimates from SWS suggest a lower market price than fair value, which can appeal if you care about what a business actually generates in cash. In this article, you will...

With inflation trends mixed, central banks cautious, and energy markets closely tied to geopolitics, many investors are looking for themes that focus on reliable and sustainable power. Nuclear energy stocks sit at the intersection of energy security and long term electricity demand, and the Nuclear Energy Stocks screener is designed to help you quickly filter this universe, from uranium producers to reactor operators, using consistent criteria. In this article, you will see 3 stocks from the...

Earlier in 2026, EVT Limited expanded its partnership with Korea-based CJ 4DPLEX to add four new ScreenX auditoriums across Australia and New Zealand, bringing its ScreenX footprint on the Event Cinemas circuit to eight. This move underlines EVT’s push to differentiate its cinemas with immersive formats like ScreenX and 4DX, aiming to draw audiences toward higher-value, premium experiences. We’ll explore how this push into more ScreenX premium auditoriums could reshape EVT’s investment...

Founder led companies sit at the intersection of commitment and accountability, where leaders often have a personal stake in how the story plays out. With global data releases, shifting inflation trends and rate expectations pulling markets in different directions, many investors are looking for businesses where leadership focus is less tied to quarterly noise and more to long term value creation. This Founder Led Companies screener helps you filter for exactly that kind of alignment. In this...

SiteMinder (ASX:SDR) has moved into focus after a double digit share price gain on high trading volume, as investors weigh its hotel commerce SaaS platform, its recurring revenue model, and its progress on key partnerships. See our latest analysis for SiteMinder. The recent spike in trading follows a sharp 45.68% 30 day share price return and 42.11% 90 day share price return, even though SiteMinder’s year to date share price return is down 33.82% and its 1 year total shareholder return is...

HomeCo Daily Needs REIT recently declared an unfranked quarterly cash distribution of A$0.0215 per unit for the June 2026 quarter, alongside a preliminary unaudited A$92 million portfolio valuation gain and reaffirmed full‑year funds‑from‑operations and distribution guidance. The combination of high portfolio occupancy and rent collection rates above 99%, plus extended debt maturities to 2028, underpins confidence in the trust’s ability to support its current income profile. We’ll now...

Investors who take an interest in ImpediMed Limited ( ASX:IPD ) should definitely note that the Independent...

Whilst it may not be a huge deal, we thought it was good to see that the EBR Systems, Inc. ( ASX:EBR ) Independent...

With inflation pressure, shifting consumer trends and mixed growth signals from regions like Europe, North America and emerging markets, many investors are looking for companies that pair earnings growth potential with balance sheet resilience. That is exactly what the Healthy high growth potential screener is built to surface, focusing on stocks where analysts expect strong earnings growth over the next 3 years while still meeting clear financial quality checks. In this article, you will see...

National Australia Bank Limited recently completed a €15 million fixed-income offering of 3.80% senior Eurobond notes due June 18, 2046, and has begun rolling out Databricks’ Genie conversational analytics tool across its analytics teams. The combination of long-dated funding and early adoption of AI-driven analytics underscores NAB’s push to strengthen both its balance sheet and data-driven decision-making. Next, we’ll explore how NAB’s Genie-powered analytics rollout could influence its...

Dividend Powerhouses with 3%+ yields can be appealing when inflation, interest rates and growth signals are pulling in different directions. With central banks weighing mixed price data and energy and food costs still volatile, many investors are looking for income streams that do not rely solely on fast economic growth. This Dividend Powerhouses screener focuses on companies paying more than a 5% dividend yield that appears covered, growing and relatively stable. In this article, you will...

Electro Optic Systems Holdings (ASX:EOS) is back in focus after securing a role for its MARSS unit in BAE Systems’ global counter drone efforts, a fresh L3Harris order, and a new European AI hub. See our latest analysis for Electro Optic Systems Holdings. All of this recent contract momentum and the new European hub comes after a period of intense trading activity for Electro Optic Systems Holdings, with the stock now at A$10.66, a 30-day share price return of 34.77% and a very large 3-year...

Earlier this week, Mesoblast reported that Ryoncil’s first-year US launch revenue approached about US$100 million, alongside continued FDA engagement on an accelerated-approval pathway and Biologics License Application for heart failure therapy Revascor. This combination of early commercial traction for Ryoncil and active regulatory dialogue on Revascor has sharpened investor focus on Mesoblast’s broader cell therapy pipeline and execution risks. We’ll now examine how Ryoncil’s early US...

Recent attention on 4DMedical (ASX:4DX) has been tied to its participation in a joint webinar with Philips and bioAffinity Technologies on diagnostic and imaging tools for U.S. veterans, alongside a recent move in the share price. See our latest analysis for 4DMedical. The recent webinar news comes on top of strong momentum in 4DMedical’s share price, with a 1 month share price return of 38.41% and a 7 day move of 23.37%. The 1 year total shareholder return is also extremely large, indicating...

In recent months, Generation Development Group reported record FY2025 results and strong growth in funds under management, while also lodging a series of routine change of director’s interest notices that have kept the company in focus. These developments, combined with sector attention on Division 296 superannuation tax legislation, underline how tax-effective investment bonds and related products are becoming increasingly relevant to investors and advisers. Next, we’ll examine how record...